Relmada Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended September 30, 2026, disclosing a net loss of $13,862,188 for the third quarter and total assets of $205,296,615 as of that date.

Key Highlights

  • Net loss for Q3 2026: $13,862,188, compared with $10,091,496 in Q3 2025, according to the filing.
  • Nine-month net loss: $45,828,329 for the nine months ended September 30, 2026, versus $37,517,403 for the same period in 2025.
  • Shares outstanding: 106,694,846 shares of common stock as of November 10, 2026, per the filing's cover page.
  • Total assets: $205,296,615 as of September 30, 2026, up from $94,003,471 as of December 31, 2025.
  • Short-term investments: $196,402,988 as of September 30, 2026, compared with $89,509,710 at year-end 2025.
  • Accumulated deficit: $744,095,527 as of September 30, 2026, per the condensed consolidated balance sheet.

Relmada Therapeutics Reports Increased Operating Losses in Third Quarter 2026

According to the filing, Relmada Therapeutics, a Nevada-incorporated biopharmaceutical company listed on NASDAQ:RLMD and headquartered in Coral Gables, Florida, reported total operating expenses of $13,096,423 for Q3 2026, up from $10,327,346 in Q3 2025. Research and development expenses rose to $9,217,440 in Q3 2026 from $4,036,267 in the prior-year quarter, while general and administrative expenses declined to $3,878,983 from $6,291,079 over the same comparison period.

The filing also reported that for the nine months ended September 30, 2026, total operating expenses reached $47,569,203, compared with $38,767,088 for the same period in 2025. Research and development spending for the nine-month period was $25,699,073 versus $18,806,667 in the prior year. The company reported interest and investment income, net, of $5,535,697 for the nine months ended September 30, 2026, partially offsetting the operating loss. Loss per common share, basic and diluted, was $0.12 for Q3 2026 and $0.44 for the nine-month period.

The condensed consolidated balance sheet showed that cash and cash equivalents were $5,720,325 and short-term investments were $196,402,988 as of September 30, 2026, compared with $3,496,540 and $89,509,710, respectively, at December 31, 2025. Total stockholders' equity stood at $193,737,061 as of September 30, 2026, an increase from $86,512,013 at December 31, 2025. The statement of changes in stockholders' equity reflected proceeds from the issuance of common stock, net, of $150,381,985 recorded during the first quarter of 2026, contributing to the increase in paid-in capital. The company reported stock-based compensation of $2,882,265 for the nine months ended September 30, 2026.

What Was Disclosed

Relmada Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a third-quarter net loss of $13,862,188, a nine-month net loss of $45,828,329, total assets of $205,296,615, and 106,694,846 shares outstanding as of November 10, 2026.